Collectively, these findings underscore the pivotal role of CD8+ TSCM cells in depression pathophysiology and highlight the potential of CXCR2 inhibitor as a therapeutic strategy to modulate gut microbiota metabolism and neuroinflammation in MDD. Here, CD8A is linked to depressive symptom measurement.